Viatris Inc. (VTRS)
VTRS Stock Price Chart
Explore Viatris Inc. interactive price chart. Choose custom timeframes to analyze VTRS price movements and trends.
VTRS Company Profile
Discover essential business fundamentals and corporate details for Viatris Inc. (VTRS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
17 Mar 1980
Employees
32.00k
Website
https://www.viatris.comCEO
Scott Andrew Smith
Description
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
VTRS Financial Timeline
Browse a chronological timeline of Viatris Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.62, while revenue estimate is $3.66bn.
Dividend declared on 22 May 2026
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 17 Jun 2026.
Earnings released on 7 May 2026
EPS came in at $0.59 surpassing the estimated $0.50 by +17.53%, while revenue for the quarter reached $3.52bn , beating expectations by +4.77%.
Dividend declared on 9 Mar 2026
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 18 Mar 2026.
Earnings released on 26 Feb 2026
EPS came in at $0.57 surpassing the estimated $0.53 by +7.14%, while revenue for the quarter reached $3.70bn , beating expectations by +4.85%.
Dividend declared on 24 Nov 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 15 Dec 2025.
Earnings released on 6 Nov 2025
EPS came in at $0.67 surpassing the estimated $0.62 by +7.89%, while revenue for the quarter reached $3.76bn , beating expectations by +3.76%.
Dividend declared on 22 Aug 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 15 Sept 2025.
Earnings released on 7 Aug 2025
EPS came in at $0.62 surpassing the estimated $0.56 by +11.51%, while revenue for the quarter reached $3.58bn , beating expectations by +3.32%.
Dividend declared on 23 May 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Jun 2025.
Earnings released on 8 May 2025
EPS came in at $0.50 surpassing the estimated $0.49 by +1.65%, while revenue for the quarter reached $3.25bn , beating expectations by +0.59%.
Dividend declared on 10 Mar 2025
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 18 Mar 2025.
Earnings released on 27 Feb 2025
EPS came in at $0.54 falling short of the estimated $0.61 by -11.48%, while revenue for the quarter reached $3.53bn , missing expectations by -2.00%.
Dividend declared on 22 Nov 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 13 Dec 2024.
Earnings released on 7 Nov 2024
EPS came in at $0.75 surpassing the estimated $0.68 by +10.78%, while revenue for the quarter reached $3.74bn , beating expectations by +0.61%.
Dividend declared on 23 Aug 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 13 Sept 2024.
Earnings released on 8 Aug 2024
EPS came in at $0.69 surpassing the estimated $0.68 by +1.77%, while revenue for the quarter reached $3.80bn , beating expectations by +0.42%.
Dividend declared on 23 May 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 14 Jun 2024.
Earnings released on 9 May 2024
EPS came in at $0.67 falling short of the estimated $0.67 by -0.45%, while revenue for the quarter reached $3.66bn , missing expectations by -0.75%.
Dividend declared on 8 Mar 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 18 Mar 2024.
Earnings released on 28 Feb 2024
EPS came in at $0.61 falling short of the estimated $0.67 by -8.96%, while revenue for the quarter reached $3.84bn , missing expectations by -0.84%.
Dividend declared on 22 Nov 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 15 Dec 2023.
Earnings released on 7 Nov 2023
EPS came in at $0.78 surpassing the estimated $0.74 by +5.41%, while revenue for the quarter reached $3.94bn , beating expectations by +1.94%.
Dividend declared on 23 Aug 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 15 Sept 2023.
Earnings released on 7 Aug 2023
EPS came in at $0.75 surpassing the estimated $0.71 by +5.63%, while revenue for the quarter reached $3.92bn , beating expectations by +1.37%.
Dividend declared on 23 May 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Jun 2023.
Earnings released on 8 May 2023
EPS came in at $0.78 surpassing the estimated $0.69 by +13.04%, while revenue for the quarter reached $3.73bn , missing expectations by -2.07%.
Dividend declared on 8 Mar 2023
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 17 Mar 2023.
Earnings released on 27 Feb 2023
EPS came in at $0.67 falling short of the estimated $0.72 by -6.94%, while revenue for the quarter reached $3.88bn , missing expectations by -2.87%.
Dividend declared on 22 Nov 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Dec 2022.
Earnings released on 7 Nov 2022
EPS came in at $0.86 surpassing the estimated $0.82 by +4.88%, while revenue for the quarter reached $4.08bn , missing expectations by -1.39%.
Dividend declared on 23 Aug 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Sept 2022.
Earnings released on 8 Aug 2022
EPS came in at $0.88 surpassing the estimated $0.81 by +8.64%, while revenue for the quarter reached $4.12bn , missing expectations by -1.63%.
Dividend declared on 23 May 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Jun 2022.
Earnings released on 9 May 2022
EPS came in at $0.93 surpassing the estimated $0.81 by +14.81%, while revenue for the quarter reached $4.19bn , missing expectations by -0.95%.
Earnings released on 28 Feb 2022
EPS came in at $0.80 falling short of the estimated $0.82 by -2.44%, while revenue for the quarter reached $4.34bn , missing expectations by -0.10%.
Dividend declared on 23 Feb 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 16 Mar 2022.
Dividend declared on 22 Nov 2021
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 16 Dec 2021.
Earnings released on 8 Nov 2021
EPS came in at $0.99 surpassing the estimated $0.86 by +15.12%, while revenue for the quarter reached $4.54bn , beating expectations by +3.31%.
Dividend declared on 23 Aug 2021
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 16 Sept 2021.
Earnings released on 9 Aug 2021
EPS came in at $0.98 surpassing the estimated $0.88 by +11.36%, while revenue for the quarter reached $4.58bn , beating expectations by +4.55%.
VTRS Stock Performance
Access detailed VTRS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
